Dobutamine-sparing versus dobutamine-to-all strategy in cardiac surgery: a randomized noninferiority trial.
Rafael Alves FrancoJuliano Pinheiro de AlmeidaGiovanni LandoniThomas W L ScheerenFilomena Regina Barbosa Gomes GalasJulia Tizue FukushimaSuely ZefferinoPasquale NardelliMarilde de Albuquerque PiccioniElisandra Cristina Trevisan Calvo AritaClarice Hyesuk Lee ParkLigia Cristina Camara CunhaGisele Queiroz de OliveiraIsabela Bispo Santos da Silva CostaRoberto Kalil FilhoFabio Biscegli JateneLudhmila Abrahão HajjarPublished in: Annals of intensive care (2021)
Although it is common practice in many centers to administer inotropes to all patients undergoing cardiac surgery, a dobutamine-sparing strategy did not result in an increase of mortality or occurrence of major cardiovascular events when compared to a dobutamine-to-all strategy. Further research is needed to assess if reducing the administration of inotropes can improve outcomes in cardiac surgery. Trial registration ClinicalTrials.gov, NCT02361801. Registered Feb 2nd, 2015. https://clinicaltrials.gov/ct2/show/NCT02361801.
Keyphrases
- cardiac surgery
- cardiovascular events
- acute kidney injury
- coronary artery disease
- patients undergoing
- cardiovascular disease
- phase iii
- study protocol
- clinical trial
- robot assisted
- phase ii
- primary care
- healthcare
- computed tomography
- risk assessment
- randomized controlled trial
- magnetic resonance imaging
- contrast enhanced
- type diabetes
- quality improvement
- risk factors
- positron emission tomography
- insulin resistance
- pet ct